伯氨喹根治缅甸东北部间日疟的疗效及CYP2D6基因型影响
2014-2017年在缅甸东北部前瞻性纳入239例无并发症间日疟患者,接受3天氯喹联合14天低剂量伯氨喹(总剂量3.5 mg/kg)直接观察治疗,随访1年。6个月累积复发风险17.3%(95%CI 11.9%-22.7%),1年25.6%(19.3%-31.9%);CYP2D6活性评分≤1.25者复发风险显著升高(OR 6.53,95%CI 2.0-21,P<.001)。
要点
- 伯氨喹根治间日疟6个月累积复发风险17.3%,1年25.6%。
- CYP2D6*36+*10串联型是最常见等位基因(34.7%)。
- CYP2D6活性评分≤1.25者复发风险显著升高(OR 6.53,P<.001)。
核心结论
- 该地区超过75%的间日疟患者携带CYP2D6活性评分≤1.25的等位基因,提示应考虑更高伯氨喹剂量。
研究设计与样本
- 2014-2017年在缅甸东北部前瞻性纳入239例无并发症间日疟患者,接受3天氯喹联合14天低剂量伯氨喹(总剂量3.5 mg/kg)直接观察治疗,随访1年。
- 嵌套病例对照研究比较49例复发患者与49例无复发患者,以CYP2D6基因型预测活性评分估计复发的未调整比值比。
主要发现
- 1年随访期间记录54例复发,其中65%发生在伯氨喹治疗后6个月内。
- 6个月累积复发风险17.3%(95%CI 11.9%-22.7%),1年累积复发风险25.6%(95%CI 19.3%-31.9%)。
- 大多数复发无症状,伴有寄生虫血症和配子体血症降低。
- CYP2D6*36+*10串联型(功能降低)为最常见等位基因(34.7%)。
- 活性评分≤1.25的患者复发风险显著更高(OR 6.53,95%CI 2.0-21,P<.001)。
关键数值与推荐
- 伯氨喹总剂量3.5 mg/kg,14天疗程,联合3天氯喹。
- CYP2D6活性评分≤1.25与复发风险升高相关(OR 6.53,95%CI 2.0-21,P<.001)。
临床怎么用
- 作者认为,该地区超过75%的间日疟患者携带CYP2D6活性评分≤1.25的等位基因,提示应考虑更高伯氨喹剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The antirelapse activity of primaquine (PQ) for Plasmodium vivax malaria depends on the host cytochrome P450 2D6 (CYP2D6) enzyme activity. This study aimed to assess the efficacy of PQ for the radical cure of P. vivax malaria in the Greater Mekong Subregion and determine the association of the post-PQ recurrences with CYP2D6 genotypes. METHODS: In 2014-2017, a total of 239 patients with uncomplicated P. vivax malaria in northeastern Myanmar were prospectively enrolled to receive a standard regimen of 3-day chloroquine and 14-day low-dose PQ (total dose, 3.5 mg/kg) as directly observed therapy. Patients were followed up biweekly for 1 year. A nested case-control study was designed to compare 49 patients with P. vivax malaria recurrences and 49 without recurrence. The CYP2D6 genotype-predicted activity score (AS) was used to estimate the unadjusted odds ratio of recurrence. RESULTS: During the 1-year follow-up, 54 recurrences were recorded with 65% occurring within 6 months after PQ treatment. The cumulative risk of recurrence was 17.3% (95% confidence interval, 11.9%-22.7%) at 6 months and 25.6% (19.3%-31.9%) at 1 year. Most recurrences were asymptomatic, with reduced parasitemia and gametocytemia. The CYP2D6*36+*10 tandem type with decreased function was the most prevalent allele (34.7%). Patients with an AS ≤1.25 had a significantly higher risk of recurrence (odds ratio, 6.53 [95% confidence interval, 2.0-21]; P < .001). CONCLUSIONS: More than 75% of patients with vivax malaria in this region carried CYP2D6 alleles with an AS ≤1.25, suggesting the consideration for higher PQ doses.
引用
- Zeng W, Liu H, Malla P, et al. Efficacy of Primaquine for the Radical Cure of Plasmodium vivax Malaria in Northeast Myanmar and the Impact of Cytochrome P450 2D6 Genotypes. Clin Infect Dis. 2025. PMID: 40152264. doi:10.1093/cid/ciae482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。